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Abstract
Background: Although viscosupplementation is an effective symptomatic treatment for knee osteoarthritis (OA),
the effect of longer term administration on articular cartilage has not been fully explored. We examined the effect
of viscosupplementation with Hylan G-F 20 on knee cartilage over 2 years in patients with knee OA.
Methods: In this prospective, single-blind, parallel control group pilot study, 78 patients with symptomatic knee
OA (Kellgren-Lawrence grade II and III) were assigned to either intervention group (n = 39 receiving 4 courses of 3
× 2.0 ml of intra-articular Hylan G-F 20 injections at 6 month intervals) or control group (n = 39 receiving usual
care for knee OA without injections). Magnetic resonance imaging of the study knee was performed at baseline, 12
and 24 months. Cartilage volume and defects were assessed using validated methods.
Results: Fifty-five subjects (71%) completed 24 month follow up. Over 24 months, the intervention group had a
reduced annual percentage rate of medial and lateral tibial cartilage volume loss (mean ± SD, -0.3 ± 2.7% and -1.4
± 4.3%) compared with the control group (2.3 ± 2.6% and 1.4 ± 2.6%, P = 0.001 and 0.005 for difference,
respectively). The intervention group also showed reduced cartilage defect score increment in the medial
tibiofemoral compartment (0.1 ± 1.3) compared with the control group (0.8 ± 1.5, P = 0.05).
Conclusions: Six monthly intra-articular injections of Hylan G-F 20 administered to patients with symptomatic knee
OA have a beneficial effect on knee cartilage preservation measured by both cartilage volume and cartilage
defects. Hylan G-F 20 warrants further evaluation in larger clinical trials as a possible disease-modifying agent in the
treatment of knee OA.
Trial Registration: The study was registered with ClinicalTrials.gov (NCT00393393).
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Background
Osteoarthritis (OA), a major cause of pain and disability,
results in significant morbidity and health care expense
[1]. Whilst OA affects the whole joint, progressive carti-
lage degeneration characterises disease progression [2].
Despite its prevalence, current non-surgical treatments
for OA relieve symptoms only; none are proven to have
any disease-modifying effect. Hyaluronic acid is impor-
tant in maintaining articular cartilage integrity, being
one of the major glycosaminoglycans in the extracellular
matrix. By binding proteoglycans, it provides and main-
tains intraarticular lubrication, optimising the viscoelas-
tic properties of synovial fluid [3]. The concentration
and molecular weight of hyaluronic acid in synovial
fluid are reduced in osteoarthritic joints, increasing car-
tilage susceptibility to mechanical stress [4].
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any medium, provided the original work is properly cited.Intra-articular injections of different forms of hyaluro-
nic acid are safe and effective in relieving pain and
improving function in knee OA over the short to med-
ium term [5,6]. Whilst intra-articular hyaluronic acid
injection is registered as a device to treat symptomatic
knee OA [5,6], evidence suggests that it may also retard
disease progression and thus be a potential disease-mod-
ifying agent. In various animal models of knee OA,
intra-articular hyaluronic acid inhibits the expression of
interleukin-1 beta and metalloproteinase-3 in synovium,
prevents proteoglycan content change in articular carti-
lage, inhibits articular cartilage degeneration, and
reduces fibrosis and synovial vascularity [7-10]. In
humans, small clinical trials employing arthroscopy with
cartilage and synovial biopsies have suggested that hya-
luronic acid administration may improve cartilage mor-
phology, reduce synovial inflammation and cartilage
deterioration over 6 months to 1 year [11-14]. However
the data is conflicting regarding the effect of sodium
hyaluronate on radiographic joint space narrowing over
1 year [14,15]. The only study examining the effect of
intra-articular hyaluronic acid on articular cartilage
assessed by magnetic resonance imaging (MRI) found
no significant difference in patellofemoral cartilage
changes between the treatment and control groups over
8 weeks [16]. However, the duration may be too short
to detect differences in cartilage changes.
H y a l nG - F2 0i sac r o s s - l i n k e df o r mo fp u r i f i e dh y a -
luronan with high molecular weight, elastoviscous fluid
with rheologic properties similar to the young healthy
human synovial fluid in the knee. The study aimed to
determine the effect of viscosupplementation on knee
structural changes by examining the effect of repeated
intra-articular injections of Hylan G-F 20 (Synvisc
®)o n
the progression of cartilage changes assessed using MRI
over 24 months in patients with symptomatic knee OA.
The hypothesis was that hyaluronic acid viscosupple-
mentation may preserve articular cartilage and retard
the progression of knee OA.
Methods
Study design and participants
This was a prospective, single-blind, parallel control
group pilot study performed in Melbourne, Australia.
Patients were recruited from rheumatology and ortho-
paedic practices. Eligibilityc r i t e r i aw e r e :a g e1 8t o8 0
years; symptomatic knee OA as defined by the American
College of Rheumatology criteria [17]; Kellgren-Lawr-
ence grade [18] of II or III on prior X-rays (taken within
6 months of the screen visit) or screen X-ray; knee pain
score ≥40 mm on a 100 mm visual analogue scale for >
15 days in the last month. Oral/parenteral corticoster-
oids (≤10 mg/day prednisolone or equivalent) and
NSAIDs were permitted if the dose had been stable for
at least one month prior to baseline. Patients were
excluded if they had unstable knee, a varus or valgus
deformity of > 15 degrees; any contraindication to MRI;
active malignancy; recent trauma (clinically defined) or
known loose bodies in the study joint; inflammatory
arthritis; concomitant medications of potent analgesics
including opiates; oral or parenteral corticosteroid ther-
apy within one month prior to enrolment into the study
other than stable doses of ≤ 10 mg daily prednisolone
or equivalent; previously received viscosupplementation
therapy within 12 months of study enrolment; arthro-
scopic or open surgery within the previous 12 months
or planned surgery to the study joint; intra-articular
injection of corticosteroid to study joint within the past
six months; morbid obesity defined as body mass index
(BMI) ≥40 kg/m
2; known sensitivity to any component
of Synvisc; or an active systemic infection.
A total of 110 subjects were assessed for eligibility; 19
failed screening prior to initial MRI (ineligible), 13 with-
drew from study prior to initiation of therapy for var-
ious reasons, generally withdrawal of consent. Therefore,
78 patients were assigned sequentially to either the
intervention (n = 39) or the control group (n = 39) and
had baseline MRI. Sixty-seven subjects attended the 12
month follow up as 11 withdrew from the study, and 55
subjects completed the 24 month follow up (Figure 1).
The study was approved by the Human Research
Ethics Committee of Cabrini Health. All patients pro-
vided written informed consent before being assigned to
study groups.
Treatment
The intervention group received 4 courses of intra-
articular Synvisc injections at 6 month intervals. Each
course consisted of three intra-articular injections of 2.0
ml Synvisc administered into the study knee at weekly
intervals. A parallel control group received no Synvisc
treatment but received usual care for OA.
All other treatments received by the patients for knee
OA remained stable for the duration of the study. This
was monitored by asking the study subjects at each
clinic visit if there had been any changes to their
NSAIDs, analgesic and physical therapies throughout
the study and documented in the study source notes.
Acute Synvisc related flares of knee pain could be mana-
ged at the investigator’s discretion with options includ-
ing aspiration of the knee, analgesics and
immobilisation. No subject received intra-articular corti-
costeroid injection.
Anthropometric data
Height was measured using a stadiometer with shoes
removed. Weight was measured with bulky clothing
removed. BMI was calculated [weight (kg)/height
2 (m
2)].
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and bone marrow lesions (BMLs)
An MRI of the study knee of each participant was per-
formed at baseline, 12 and 24 months. Knees were
imaged in the sagittal plane on a 1.5-T whole body mag-
netic resonance unit (Signa Advantage HiSpeed; General
Electric Medical Systems, Milwaukee, WI, USA) using a
commercial transmit-receive extremity coil, with
 
Assessed for eligibility (n=110) 
Excluded (n=32) 
  Not meeting inclusion criteria 
(n=19) 
  Declined to participate (n=13) 
Analysed (n=25) 
  withdrew due to surgery or planned 
surgery of study knee (n=6);  
  withdrew due to family issues (n=1) 
Allocated to intervention 
(n=39) 
  withdrew due to personal reason 
or diagnosed colon cancer (n=3);  
  lost to follow-up (n=1) 
Allocated to control 
(n=39) 
Analysed (n=30) 
Allocation 
Analysis 
1 year Follow-Up 
Allocated (n=78) 
Enrolment 
2 year Follow-Up 
  withdrew due to surgery of study knee (n=3)  
  withdrew due to too much travel (n=2) 
  withdrew due to family issues (n=1) 
  withdrew due to not interested (n=1) 
  withdrew due to surgery or increased 
pain of study knee (n=3)  
  withdrew due to personal reason (n=1) 
  lost to follow-up (n=1) 
Figure 1 Study profile.
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Page 3 of 9previously described sequences and parameters [19].
Each cartilage and bone measure was performed by one
trained observer (F.H for cartilage volume, C.X for carti-
lage defects and tibial bone area, and M.D. for BMLs)
with independent random cross checks performed by a
second observer (Y.W), using the software Osiris (Uni-
versity Hospitals of Geneva, Switzerland) and ImageJ
(National Institutes of Health, USA). All MRI images
were analysed unpaired, blinded to patient group, data
collected, and sequence.
Tibial cartilage volume and bone areas were measured
using validated methods [19]. The coefficients of varia-
tion for the medial and lateral tibial cartilage volume
measures were 3.4% and 2.0%, respectively [19]. The
coefficients of variation for the medial and lateral tibial
plateau bone area measures were 2.3% and 2.4%, respec-
tively [19].
Cartilage defects were graded in the medial and lateral
tibial and femoral cartilages [20]: grade 0, normal carti-
lage; grade 1, focal blistering and intracartilaginous low-
signal intensity area with an intact surface and bottom;
grade 2, irregularities on the surface or bottom and loss
of thickness of < 50%; grade 3, deep ulceration with loss
of thickness of ≥ 50%; grade 4, full-thickness cartilage
wear with exposure of subchondral bone. If more than
one cartilage defect was found in a cartilage plate, the
highest grade was recorded. Intra- and inter-observer
reliability (expressed as intraclass correlation coefficient)
was 0.90 and 0.90 for the medial, 0.89 and 0.85 for the
lateral tibiofemoral compartment, respectively [20]. The
grades of tibial (0-4) and femoral (0-4) cartilage defects
were added up as tibiofemoral cartilage defect score in
the medial (0-8) and lateral (0-8) compartment,
separately.
BMLs were defined as areas of increased signal inten-
sity within the subchondral bone regions in distal femur
or proximal tibia on coronal T2-weighted fat-saturated
images [21]. The reproducibility for determination of
BMLs was high (Kappa = 0.88, P < 0.001). A BML was
defined as present if it appeared on two or more adja-
cent slices, encompassing at least one quarter of the
width of medial or lateral compartment.
Statistical analyses
With 39 subjects in each arm of the study, we had 80%
power to show a 60% difference in the amount of knee
cartilage loss over 2 years in the intervention group
compared to the control group. This is based on our
published MRI data of the amount of cartilage loss [22].
We anticipated a 2% annual cartilage volume loss in the
intervention group compared to 5% in the control group
(SD 5%). T-tests were used for comparison of means.
Mann-Whitney U test was used to compare medians.
Chi-squared test was used to compare nominal
characteristics between theg r o u p s .T h ep r i m a r yo u t -
come measures were annual percentage change in tibial
cartilage volume and change in cartilage defect score
over time. The annual percentage change of cartilage
volume was calculated by:
initial volume − second volume
(initial volume)(time between scans)
× 100%
Change in tibiofemoral cartilage defect score was
determined by subtracting baseline tibiofemoral defect
score from follow-up tibiofemoral defect score. Out-
come measures were initially assessed for normality
before being regressed against exposure variables, thus
general linear models were used to explore the relation-
ship between intervention and outcome measures
adjusting for potential confounders. All analyses were
performed on completers. P < 0.05 (two-tailed) was
regarded as statistically significant. All analyses were
performed using the SPSS statistical package (version
16.0.0, SPSS, Cary, NC).
Results
Seventy-eight patients were assigned to either the inter-
vention (n = 39) or the control group (n = 39). There
were no significant baseline differences between the two
groups apart from the prevalence of medial tibiofemoral
BMLs being higher in the control group compared with
the intervention group (Table 1).
Sixty-seven (86%) subjects completed 12 month MRI
follow up and 55 (71%) completed 24 month MRI fol-
low up. The mean time between baseline and follow
up MRI scans was 1.0 (SD 0.06, range 0.8-1.2) year
a n d2 . 2( S D0 . 2 ,r a n g e1 . 9 - 3 . 2 )y e a r s .T h e r ew e r en o
significant differences between those who completed
the 12 month or 24 month follow up and those who
did not in terms of age, gender, BMI, knee cartilage
and bone area measures. The 55 completers were simi-
lar at baseline to the original 78 subjects. There were
no significant differences in baseline characteristics of
completers in the intervention (n = 25) and control (n
= 30) groups, except that the control group had more
prevalent medial tibiofemoral BMLs and tended to
have greater lateral tibial cartilage volume, compared
with the intervention group (Table 2). To examine the
effect of intervention on cartilage changes over 12 and
24 months consistently and avoid the results being
biased by any difference between the two subgroup
populations (67 vs. 55 subjects), the following analyses
were based on the 55 participants who completed both
12 and 24 month follow ups. However, similar results
were observed when examining cartilage changes from
baseline to 12 month follow up on the 67 participants
(data not shown).
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From baseline to 12 months, the annual percentage
changes in medial and lateral tibial cartilage volume
were 1.4 ± 5.2% (P = 0.21, difference from zero change)
and 2.8 ± 6.8% (P = 0.05), respectively for the interven-
tion group, with significant loss in lateral tibial cartilage.
In the control group, the annual percentage change was
3.3 ± 4.4% (P < 0.001) in the medial and1.0 ± 5.9% (P =
0.37) in the lateral tibial cartilage volume, with signifi-
cant loss in medial tibial cartilage. However, there were
no significant differences in annual percentage tibial car-
tilage volume changes between the intervention and
control groups in either compartment (Table 3).
Over 24 months, whilst in the intervention group
there was no significant annual percentage change in
t h em e d i a l( - 0 . 3±2 . 7 % ,P=0 . 6 0 )a n dl a t e r a l( - 1 . 4±
4.3%, P = 0.12) tibial cartilage volumes, in the control
group significant cartilage loss was seen in medial (2.3 ±
2.6%, P < 0.001) and lateral (1.4 ± 2.6%, P = 0.01) tibial
cartilage volumes. The annual percentage cartilage loss
Table 1 Baseline characteristics of study population
Intervention
n=3 9
Control
n=3 9
P value*
Age, years 61.3 (9.6) 61.4 (9.8) 0.97
Females, number (%) 19 (54) 14 (40) 0.23†
Body mass index, kg/m
2 29.8 (3.7) 29.2 (4.8) 0.57
Kellgren-Lawrence grade, number (%) 0.43
2 28 (72) 31 (79)
3 11 (28) 8 (21)
Joint space narrowing, number (%) 38 (97) 38 (97) 1.00
Medial tibial cartilage volume, mm
3 1512 (552) 1420 (624) 0.51
Lateral tibial cartilage volume, mm
3 1691 (832) 1878 (685) 0.31
Medial tibial plateau bone area, mm
2 2391 (400) 2537 (522) 0.20
Lateral tibial plateau bone area, mm
2 1756 (335) 1841 (417) 0.35
Medial tibiofemoral cartilage defect score 5 [1, 8] 6 [1, 8] 0.15§
Lateral tibiofemoral cartilage defect score 3 [1, 8] 3 [0, 8] 0.32§
Prevalence of medial tibiofemoral bone marrow lesions, number (%)** 9 (38) 18 (72) 0.02†
Prevalence of lateral tibiofemoral bone marrow lesions, number (%)** 7 (29) 8 (32) 0.83†
Data were reported as mean (SD), median [range], or number (%)
*for difference between intervention and control groups using independent samples t test, Mann-Whitney U test§, or chi-squared test† where appropriate
**Bone marrow lesion data available in 24 subjects of intervention group and 25 subjects of control group who completed 24 month follow up
Table 2 Baseline characteristics of participants who completed 2 year follow up
Intervention
n=2 5
Control
n=3 0
P value*
Age, years 61.6 (9.4) 61.3 (9.5) 0.89
Females, number (%) 15 (60) 12 (40) 0.14†
Body mass index, kg/m
2 30.3 (3.9) 28.9 (4.5) 0.23
Kellgren-Lawrence grade, number (%) 0.10
2 16 (64) 25 (83)
3 9 (36) 5 (17)
Joint space narrowing, number (%) 24 (96) 29 (97) 0.90
Medial tibial cartilage volume, mm
3 1488 (540) 1439 (619) 0.76
Lateral tibial cartilage volume, mm
3 1485 (748) 1881 (720) 0.05
Medial tibial plateau bone area, mm
2 2359 (415) 2503 (515) 0.27
Lateral tibial plateau bone area, mm
2 1738 (325) 1827 (409) 0.38
Medial tibiofemoral cartilage defect score 4 [1, 8] 6 [1, 8] 0.08§
Lateral tibiofemoral cartilage defect score 4 [1, 8] 2.5 [0, 8] 0.23§
Prevalence of medial tibiofemoral bone marrow lesions, number (%)** 9 (38) 18 (72) 0.02†
Prevalence of lateral tibiofemoral bone marrow lesions, number (%)** 7 (29) 8 (32) 0.83†
Data were reported as mean (SD), median [range], or number (%)
*for difference between intervention and control groups using independent samples t test, Mann-Whitney U test§, or chi-squared test† where appropriate
**Bone marrow lesion data available in 24 subjects of intervention group and 25 subjects of control group who completed 24 month follow up
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Page 5 of 9was significantly higher in the control group compared
with the intervention groups in both compartments
(Table 3).
The results were similar after adjusting for age, gen-
der, BMI, baseline tibial cartilage volume and bone area
at both 12 and 24 months (Table 3). Adding the preva-
lence of BMLs in the models did not alter the findings
(data not shown).
Effect of intervention on change in tibiofemoral cartilage
defects
From baseline to 12 months, the intervention group had
a significant increase in cartilage defect score in the
medial (0.4 ± 0.7, P = 0.02, difference from zero change)
and lateral (0.2 ± 0.4, P = 0.04) compartments, while
there was no significant change in cartilage defect score
in the control group (0.1 ± 0.5, P = 0.26 and 0.2 ± 1.0,
P = 0.28, respectively). However, the difference in
change in cartilage defect score between the interven-
tion and control groups was not statistically significant
(Table 4).
Over 24 months, while there was no significant
change in cartilage defect score in the intervention
group in the medial (0.1 ± 1.3, P = 0.75) or lateral (0.4
± 1.3, P = 0.10) compartment, the control group had a
significant increase in cartilage defect score in both
compartments (0.8 ± 1.5, P = 0.005 and 0.8 ± 1.4, P =
0.003, respectively). The cartilage defect score in medial
compartment in the control group increased signifi-
cantly more than in the intervention group (P = 0.05)
(Table 4).
The results were similar after adjusting for age, gen-
der, BMI, and baseline cartilage defect score at both 12
and 24 months (Table 4). Adding the prevalence of
BMLs in the models did not alter the findings (data not
shown).
Discussion
This prospective, single-blind, parallel control group
pilot study reported the effect of repeated courses of
Hylan G-F 20 on knee cartilage assessed using MRI over
2 years. The Hylan G-F 20 treated group showed
Table 3 The effect of intervention on annual percentage change in tibial cartilage volume
Mean Adjusted
mean*
Intervention
Mean (SD)
Control
Mean
(SD)
Difference†
Mean (95%
CI)
P
value†
Intervention
Mean (SE)
Control
Mean
(SE)
Difference†
Mean (95% CI)
P
value†
From baseline to 12 month follow
up
Medial tibial cartilage 1.4 (5.2) 3.3 (4.4) 1.9 (-0.7, 4.5) 0.15 1.3 (1.0) 3.3 (0.9) 2.0 (-0.8, 4.9) 0.16
Lateral tibial cartilage 2.8 (6.8) 1.0 (5.9) -1.8 (-5.3, 1.6) 0.29 3.3 (1.3) 0.6 (1.1) -2.7 (-6.2, 0.7) 0.12
From baseline to 24 month follow
up
Medial tibial cartilage -0.3 (2.7) 2.3 (2.6) 2.6 (1.2, 4.1) 0.001 -0.4 (0.6) 2.4 (0.5) 2.7 (1.2, 4.3) 0.001
Lateral tibial cartilage -1.4 (4.3) 1.4 (2.6) 2.8 (0.9, 4.7) 0.005 -1.3 (0.7) 1.3 (0.6) 2.6 (0.6, 4.5) 0.01
*Estimated marginal mean, adjusting for age, gender, body mass index, baseline tibial cartilage volume and bone area
†for difference between intervention and control groups
Table 4 The effect of intervention on change in cartilage defect score from baseline to follow up
Mean Adjusted
mean*
Intervention
Mean (SD)
Control
Mean
(SD)
Difference†
Mean (95%
CI)
P
value†
Intervention
Mean (SE)
Control
Mean
(SE)
Difference†
Mean (95% CI)
P
value†
From baseline to 12 month follow
up
Medial tibiofemoral 0.4 (0.7) 0.1 (0.5) -0.3 (-0.6, 0.1) 0.11 0.4 (0.1) 0.1 (0.1) -0.3 (-0.6, 0.1) 0.15
Lateral tibiofemoral 0.2 (0.4) 0.2 (1.0) 0.04 (-0.4, 0.5) 0.85 0.2 (0.2) 0.2 (0.1) -0.1 (-0.5, 0.4) 0.78
From baseline to 24 month follow
up
Medial tibiofemoral 0.1 (1.3) 0.8 (1.5) 0.8 (0, 1.5) 0.05 0.04 (0.3) 0.9 (0.3) 0.8 (0, 1.7) 0.05
Lateral tibiofemoral 0.4 (1.3) 0.8 (1.4) 0.4 (-0.4, 1.1) 0.33 0.5 (0.3) 0.7 (0.2) 0.2 (-0.5, 0.9) 0.56
*Estimated marginal mean, adjusting for age, gender, body mass index, and baseline cartilage defect score
†for difference between intervention and control groups
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cartilage defect score compared with the control group
over 24 months, independent of age, gender, BMI, and
baseline cartilage and bone characteristics.
Although intra-articular hyaluronic acid injections
have beneficial effects on articular cartilage and syno-
vium assessed by arthroscopy [11-14], their effect on
radiographic characteristics of knee OA has been incon-
sistent. While a small study of 36 patients showed no
effect of the intervention on joint space narrowing
reduction over 1 year [14], a randomised, placebo-con-
trolled clinical trial in 273 patients found significantly
less progression of joint space narrowing over 1 year
associated with the intervention in patients with radiolo-
gically milder disease but not in those with radiologi-
cally more severe OA [15]. However, radiographic joint
space narrowing is an indirect measurement of cartilage
thinning and insensitive to change [23]. In contrast,
MRI allows direct visualization of all components of the
knee joint simultaneously and noninvasively, providing
accurate quantification of articular cartilage which is
sensitive to longitudinal change [24,25].
T h eo n l ys t u d ye x a m i n i n gt h eeffect of intra-articular
hyaluronic acid injections on articular cartilage assessed
by MRI detected significant difference in patellofemoral
cartilage defects over 8 weeks in the hyaluronic acid
group, but it was not significant compared to the con-
trol group [16]. However, the small sample size (n = 30)
and short time span of the study limited its ability to
draw strong conclusion on the effect of intra-articular
hyaluronic acid injections on articular cartilage [16]. We
used a validated MRI protocol, providing accurate and
reproducible quantitation of knee cartilage with 2 years
follow up [24,25]. While at 12 months a trend towards
less medial tibial cartilage loss was observed in the inter-
vention group compared with the control group, at 24
months, intra-articular Hylan G-F 20 injections were
associated with significantly reduced disease progression
measured by both cartilage volume and defects: knee
OA progression is associated with worsening of cartilage
defects and reduced cartilage volume.
Cartilage volume loss measured from MRI is asso-
ciated with worsening of knee symptoms [19] and
increased risk of knee joint replacement [24]. Cartilage
defects are associated with knee pain, cartilage break-
down, predict cartilage loss and knee joint replacement
[20,25,26]. Thus we showed a beneficial effect of intra-
articular Hylan G-F 20 injections on knee cartilage.
Furthermore, the effect was more evident in the medial
tibiofemoral compartment, the most common site of
OA involvement at the knee. As the medial compart-
ment is exposed to increased forces through the knee
during weight-bearing activities [27] and increased joint
loading plays a key role in the progression of knee OA
[28], the medial compartment is more vulnerable to dis-
ease progression. Our findings suggest intra-articular
Hylan G-F 20 may have the potential to retard the pro-
gression of knee OA and serve as a possible disease-
modifying agent for OA which warrant further evalua-
tion in larger clinical trials.
Although the mechanisms of the action of hyaluronic
acid on articular cartilage still remain unclear, stimula-
tion of endogenous hyaluronan and cartilage matrix
synthesis, inhibition of cartilage degradation and inflam-
matory mediators may play a role [29,30]. The adminis-
tration of repeat courses of sodium hyaluronate or
Hylan G-F 20 over 1~2 years is safe and effective for
pain relief in knee OA [31,32]. However, little informa-
tion is available regarding the effect of repeat courses of
sodium hyaluronate on knee structural changes [14,15].
In our study, the patients received 4 courses of Hylan
G-F 20 every 6 months over 2 years where repeated
intra-articular injections of Hylan G-F 20 reduced knee
cartilage loss in both tibiofemoral compartments over 2
years with a trend suggesting reduced cartilage loss in
the medial compartment over 1 year. It may be that we
did not have power to show an effect over that shorter
time period. The findings suggest that Hylan G-F 20
may have sustained effect on the preservation of knee
cartilage and the effect is more evident with repeat
administration over a longer time. Therefore repeated
courses may be required to benefit cartilage. This will
need to be examined in larger studies.
This study has limitations. Being a single-blind, paral-
lel control group pilot study, participants were not ran-
domly assigned to the intervention and control arms
and no placebo control was performed. Although the
baseline characteristics of the two groups were similar
in terms of age, gender, BMI, knee cartilage and bone
area measures, it is likely that other risk factors for OA
progression such as knee malalignment and meniscal
pathology, were different between the two groups.
Although patients with unstable knee, a varus or valgus
deformity of > 15 degrees were excluded from the study,
we were not able to control for the confounding of
those variables that we did not collect data on. The ana-
lysis was based on objective validated structural mea-
sures not subjective measures of symptoms. The
presented analyses were based on the 55 of 78 (71%) of
subjects who completed 24 month follow up and so will
need to be interpreted with caution. Although the rate
of loss to follow up was 29%, the 55 completers had
similar baseline characteristics to the original 78 sub-
jects, and the baseline characteristics of the 55 subjects
in the intervention and control groups were similar.
There were 9 patients in the treatment group who with-
drew due to surgery or scheduled surgery of the study
knee and therefore were not included in the final
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Page 7 of 9analysis (vs. 3 patients in the control group). This may
have introduced selection bias that resulted in a better
progression profile in the treatment group compared
with the control group and therefore biased the results
toward a protective effect of Hylan G-F 20. BMLs, a pre-
dictor of OA progression [21], were more prevalent in
the control group compared with the treatment group.
This may provide an alternative explanation of the
increased OA progression we observed in the control
group. However, BMLs were adjusted for in the analysis
and the findings did not change. Randomized clinical
trials will be needed to minimize selection bias and con-
trol for confounding. The strength of the study was the
independently performed measurement of cartilage
volume and defects, by independent experienced obser-
vers, who were blinded to both the intervention/control
status of the participants and sequence of images.
Conclusions
Although this is a pilot study with only moderate sam-
ple size, the findings suggest that 6 monthly intra-articu-
lar injections of Hylan G-F 20 administered to patients
with symptomatic knee OA have beneficial effect on
knee cartilage preservation, measured by both cartilage
volume and cartilage defects. Over 24 months the con-
trol group continued to lose cartilage while there was
no significant cartilage loss in the Hylan G-F 20 treated
group. This use of Hylan G-F 20 warrants further eva-
luation in larger randomized, double-blind, placebo-con-
trolled trials as a possible disease-modifying agent in the
treatment of knee OA.
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